Saturday - November 23, 2024
UT-MD Anderson Cancer Center: ESMO - Novel ADC AZD8205 Demonstrates Manageable Safety Profile and Preliminary Efficacy in First-in-Human Trial
September 14, 2024
HOUSTON, Texas, Sept. 14 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:

* * *

Partial responses were seen in ovarian, breast and endometrial cancers

* * *

ABSTRACT: 606O (https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/show/session/30)

BARCELONA, Spain - The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products